Navigation Links
China Yongxin Pharmaceuticals Reports First Quarter 2010 Financial Results

CHANGCHUN, China and LOS ANGELES, May 24 /PRNewswire-Asia/ -- China Yongxin Pharmaceuticals Inc. (OTC Bulletin Board: CYXN) ("the Company"), one of the leading health products distribution and retail sales companies in China, today announced its financial results for the first quarter ending March 31, 2010.

Revenues for the first quarter of 2010 were $10.68 million, a 16.3% increase from $9.18 million for the same period of 2009. Revenues from retail drug stores for the first quarter of 2010 were $3.99 million, an increase of 19.5% compared to $3.34 million for the first quarter of 2009. Revenues from the wholesale pharmaceutical distribution business for the first quarter of 2010 were $7.69 million, an increase of 7.0% from $7.19 million for the first quarter of 2009.

A substantial portion of the increase in sales was attributable to the Chinese government's national medical insurance program and its provision for National Essential Drug List which drugs are allowed for healthcare reimbursement by recipients. Approximately 95% of Yongxin's drugs are included in the National Essential Drug List.

The cost of goods sold for the first quarter of 2010 was $8.28 million, an increase of 1.8% compared to $6.95 million for the first quarter of 2009. The slight increase was due to the increased sales of seasonal medications driven by market demand, such as cold medicine and antibiotics, the sales of which typically increase during the winter cold and flu season. Gross profit for the first quarter of 2010 was $2.40 million compared to $2.23 million for the same period in 2009.

Net income increased to $2.35 million for the first quarter of 2010, a 505.3% increase over the $0.39 million for the first quarter of 2009. The increase was primarily due to the sale of the Company's digital e-learning business during the first quarter of 2010 in which we were able to eliminate approximately $1.9 million of liabilities associated with the e-learning business. As part of its strategic plan, it was the Company's intention to divest the digital e-learning business and focus on its core business.

Fully diluted earnings per share increased to $0.04 for the first quarter of 2010 compared to $0.01 for the first quarter of 2009, based on 59.6 million shares and 31.0 million shares for the first quarter of 2010 and 2009, respectively.

Operating expenses for the first quarter of 2010 were $1.64 million, compared to $1.16 million for the first quarter of 2009. Selling expenses for the first quarter of 2010 were $0.79 million, a decrease of 3.2% from $0.82 million for the first quarter of 2009. The decrease was mainly attributable to better control of selling expenses through certain cost-cutting efforts such as the reduction of utilities usage, office supplies and changes in the packaging of products. General and administrative expenses for the first quarter of 2010 increased approximately 150% to $0.85 million, compared to $0.34 million in the same period of 2009. The increase was primarily due to an increase in accrued litigation settlement costs, and the settlement of such litigation is expected to be a non-recurring expense.

As of March 31, 2010, the Company had approximately $2.00 million in cash and cash equivalents, current assets of $33.39 million and total liabilities of $13.69 million.

Mr. Yongxin Liu, Chairman and Chief Executive Officer of China Yongxin commented, "During the first quarter of 2010, we were selected as the sole pharmaceutical distributor for the Shenyang Military Region medical centers located throughout three of China's northeast region provinces, including Jilin, Liaoning and Heilongjiang, and one of the qualified distributors for Jilin province. We have also opened six new drug stores including three in Changchun City and three in Baishan City. This is in line with our strategy to further our new retail oriented sales strategy. We plan to open an additional 35 new retail stores in 2010, including 15 additional retail stores located in Changchun City, ten retail stores in Baishan City and ten retail stores in Tianjin City. The opening of new stores will continue to reflect the growth of our retail drugstore business to drive revenue growth."

Mr. Liu also added, "Our steady revenue growth, especially growth from our retail business in the first quarter of 2010, we believe indicates that our business is well-positioned to take advantage of increased government support for expanded health care. In 2010, the government accelerated implementation of its reforms, extending benefits to rural areas. We are very confident that the Chinese Government's efforts toward healthcare reform will continue to boost domestic spending on the products we sell. "

About China Yongxin Pharmaceuticals Inc.

Founded in 1993, China Yongxin Pharmaceuticals is one of the leading retailers and distributors of Chinese traditional medicines, pharmaceutical preparations, natural health products, health food, cosmetics, and medical equipment in Northeastern China. Its retail operations began in 2004, and in 2005, it gained franchise rights from one of the world's largest drug chains for China's Jilin Province. The Company had become one of the fastest growing drug retailers in China through its retail chain of 99 drug outlets as well as its wholesale distribution in Northeastern China. For more information about China Yongxin Pharmaceuticals, please visit .

Forward Looking Statements

This news release contains certain "forward-looking statements." Forward- looking statements are based on current expectations and assumptions and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, and many of which are beyond the Company's control. The forward-looking statements are also identified through the use of words "believe," enable," "may," "will," "could," "intends," "estimate," "anticipate," "plan," "predict" "probable," "potential," "possible," "should," "continue," "project", "expect" and other words of similar meaning. Actual results could differ materially from these forward-looking statements as a result of a number of risk factors detailed in the Company's periodic reports filed with the SEC. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements and no assurances can be given that such statements will be achieved. China Yongxin Pharmaceuticals Inc. does not assume any duty to publicly update or revise the material contained herein.

    For more information, please contact:

     China Yongxin Pharmaceuticals Inc.
     Sam Liu, COO
     Tel:   +1-626-581-9098

     Strategic Growth International, Inc.
     Richard Cooper / Linda Ni
     Tel:   +1-212-838-1444
     Email: ;

SOURCE China Yongxin Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... potential to use SyMRI to find optimal contrast weighting of ... tumor metastases, and has signed a research agreement with SyntheticMR ... the hospital. Using SyMRI, it is possible to generate multiple ... settings after the patient has left, thus making it possible ...
(Date:11/26/2015)... 2015 ... the  "2016 Future Horizons and Growth ... Testing Market: Supplier Shares, Competitive Intelligence, ... --> ) has ... Future Horizons and Growth Strategies in ...
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... --> adds "Global ... and "Investigation Report on China Repaglinide ... 2021 forecasts data and information to ... . --> ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... Keeping in mind ... mental health and wellness consultation, has collaborated with a leading web-based marketplace for ... gap experienced by parents and bring advice from parenting experts within their reach. ...
(Date:11/27/2015)... ... November 27, 2015 , ... The ... and prominent nonprofit healthcare organizations in the country. They have overseen financial turnarounds, ... and helped advance the healthcare industry as a whole through their advocacy and ...
(Date:11/27/2015)... California (PRWEB) , ... November 27, 2015 , ... Avid ... Joplin Ann Arbor Michigan boxing style concert posters. This is one of Joplin's most ... the Canterbury House at the University of Michigan in Ann Arbor. The According to ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... located in central Michigan, have come together on Thanksgiving Day to share the ... available for viewing on the Serenity Point YouTube channel, patients displayed what they ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... ... a real-time eReferral system for diagnostic imaging in the Waterloo region. Using the ... and Nuclear Medicine tests directly from their electronic medical record (EMR) without the ...
Breaking Medicine News(10 mins):